Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2018 | EMIF-AD: data sharing for better research

Pieter Jelle Visser • 22 Jul 2018
AAIC 2018
Alzheimer’s Disease Dementia

Vast quantities of data are produced from studies; however, this data is rarely aggregated into larger sets, limiting its potential use. The European Medical Information Framework (EMIF) platform is developing a framework to enhance access to human health data across Europe for a range of diseases, including Alzheimer’s disease (EMIF-AD). Speaking from the Alzheimer’s Association International Conference (AAIC) 2018, held in Chicago, IL, Pieter Jelle Visser, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses the benefits of EMIF-AD in advancing Alzheimer’s research.

More from Pieter Jelle Visser

Amyloid aggregation in cognitively healthy, elderly identical twins
1:57
Amyloid aggregation in cognitively healthy, elderly identical twins
Pieter Jelle Visser • 22 Jul 2018
EMIF-AD studies: cardiovascular health and risk of dementia
2:28
EMIF-AD studies: cardiovascular health and risk of dementia
Pieter Jelle Visser • 22 Jul 2018
A framework for easy access to Alzheimer's disease data
1:03
A framework for easy access to Alzheimer's disease data
Pieter Jelle Visser • 29 Aug 2017
The lack of new data for Alzheimer's disease research: what can be done?
0:33
The lack of new data for Alzheimer's disease research: what can be done?
Pieter Jelle Visser • 30 Aug 2017

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals